| Active Not Recruiting | Malnutrition Screening and Dietary Intervention to Improve Nutrition Outcomes in Patients With Unresectable Pa NCT06090916 | Jonsson Comprehensive Cancer Center | N/A |
| Terminated | Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancr NCT05631574 | Biomea Fusion Inc. | Phase 1 |
| Active Not Recruiting | A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer NCT03899636 | Angiodynamics, Inc. | Phase 3 |
| Active Not Recruiting | A Registry Study of NanoKnife IRE for Stage 3 Pancreatic Cancer NCT03899649 | Angiodynamics, Inc. | — |
| Active Not Recruiting | Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer NCT03825289 | University of Utah | Phase 1 |
| Recruiting | Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors NCT03682289 | Rahul Aggarwal | Phase 2 |
| Active Not Recruiting | TAS102 in Combination With NAL-IRI in Advanced GI Cancers NCT03368963 | Emory University | Phase 1 / Phase 2 |
| Completed | VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer NCT03373188 | Emory University | Phase 1 |
| Completed | Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer NCT03154190 | Stanford University | N/A |
| Completed | Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer NCT03095781 | Emory University | Phase 1 |
| Completed | Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors NCT02897375 | Emory University | Phase 1 |
| Completed | Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic NCT02896907 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | EARLY_Phase 1 |
| Completed | BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer NCT02620865 | Barbara Ann Karmanos Cancer Institute | Phase 1 / Phase 2 |
| Active Not Recruiting | Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or NCT02495896 | University of Southern California | Phase 1 |
| Terminated | Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study NCT02345460 | Case Comprehensive Cancer Center | Phase 2 |
| Completed | Electronic Monitoring Device of Patient-Reported Outcomes and Function in Improving Patient-Centered Care in P NCT02511821 | City of Hope Medical Center | N/A |
| Withdrawn | Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Tr NCT02048943 | Roswell Park Cancer Institute | Phase 1 |
| Completed | Neoadjuvant Chemotherapy Followed by Radiation Therapy and Gemcitabine/Sorafenib/Vorinostat in Pancreatic Canc NCT02349867 | Virginia Commonwealth University | Phase 1 |
| Completed | Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or NCT02227940 | Roswell Park Cancer Institute | Phase 1 |
| Completed | Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer NCT02333188 | University of Chicago | Phase 1 |
| Withdrawn | Palliative Care in Improving Quality of Life and Symptoms in Patients With Stage III-IV Pancreatic or Ovarian NCT01927393 | City of Hope Medical Center | N/A |
| Completed | APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Me NCT02166255 | Wake Forest University Health Sciences | Phase 1 |
| Completed | Palliative Care in Improving Quality of Life in Patients With Newly Diagnosed Pancreatic Cancer NCT02307539 | City of Hope Medical Center | N/A |
| Withdrawn | Patient Derived Cancer Cell Lines in Identifying Molecular Changes in Patients With Previously Untreated Pancr NCT02414100 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | — |
| Completed | Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointe NCT01846520 | City of Hope Medical Center | N/A |
| Completed | Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer NCT01959672 | University of Nebraska | Phase 2 |
| Completed | Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer NCT01924260 | Edward Kim | Phase 1 |
| Terminated | High or Standard Intensity Radiation Therapy After Gemcitabine Hydrochloride and Nab-paclitaxel in Treating Pa NCT01921751 | Radiation Therapy Oncology Group | Phase 2 |
| Completed | CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer NCT01839981 | Wake Forest University Health Sciences | Phase 1 |
| Completed | Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients with Pancreatic NCT01821612 | Alliance for Clinical Trials in Oncology | EARLY_Phase 1 |
| Terminated | Chemoradiation and Radiosurgery Boost in Treating Patients With Locally Advance Pancreatic Cancer That May or NCT01739439 | Fox Chase Cancer Center | Phase 1 |
| Completed | Ultrasound-Guided Photodynamic Therapy With Photofrin & Gemcitabine for Patients With Locally Advanced Pancrea NCT01770132 | John DeWitt | Phase 1 |
| Completed | ADH-1, Gemcitabine Hydrochloride & Cisplatin in Treating Metastatic Pancreatic or Biliary Tract Cancer NCT01825603 | University of Nebraska | Phase 1 |
| Completed | Gemcitabine Hydrochloride in Treating Patients With Locally Advanced Pancreatic Cancer NCT01893294 | Mayo Clinic | Phase 1 |
| Completed | Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors NCT01525082 | Shaheen Shagufta | Phase 2 |
| Completed | Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer NCT01473940 | Northwestern University | Phase 1 |
| Completed | Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastati NCT01497392 | Roswell Park Cancer Institute | Phase 1 |
| Completed | Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointest NCT01643499 | University of Chicago | Phase 1 |
| Terminated | Gemcitabine Hydrochloride, and Radiation Therapy in Patients With Borderline Resectable Pancreatic Cancer NCT01897454 | Albert Einstein College of Medicine | Phase 2 |
| Completed | Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer NCT01191684 | City of Hope Medical Center | Phase 1 |
| Completed | Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreati NCT01234935 | Translational Oncology Research International | Phase 2 |
| Terminated | Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Ur NCT01282333 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Ca NCT01222689 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Gamma-Secretase Inhibitor RO4929097 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tum NCT01145456 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors NCT01131234 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Stereotactic Radiation, Nelfinavir Mesylate & Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer NCT01068327 | University of Nebraska | Phase 1 |
| Terminated | Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery NCT00482625 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Sunitinib and Gemcitabine in Treating Patients With Pancreatic Cancer or Other Solid Tumors NCT00462553 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer P NCT00383760 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pan NCT01534637 | Wake Forest University Health Sciences | Phase 2 |
| Unknown | Weekly Dosing of an Integrative Chemotherapy Combination to Treat Advanced Pancreatic Cancer NCT00323583 | Seattle Cancer Treatment and Wellness Center | Phase 2 |
| Completed | Capecitabine, Bevacizumab, and Radiation Therapy Followed By Gemcitabine and Bevacizumab in Treating Patients NCT00114179 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidne NCT00101348 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Radiotherapy Combined With Oxaliplatin and Fluorouracil Followed By Gemcitabine in Treating Patients With Loca NCT00096070 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Sorafenib and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer NCT00095966 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pan NCT00091026 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Triapine as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Cancer NCT00085371 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Ca NCT00088894 | National Cancer Institute (NCI) | Phase 3 |
| Terminated | EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer NCT00087191 | National Cancer Institute (NCI) | N/A |
| Completed | CCI-779 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer NCT00075647 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Erlotinib, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreat NCT00063947 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Flavopiridol Plus Radiation Therapy Followed By Gemcitabine Hydrochloride in Treating Patients With Locally Ad NCT00047307 | National Cancer Institute (NCI) | Phase 1 |
| Completed | UCN-01 and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer NCT00039403 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer NCT00031694 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Bevacizumab and Gemcitabine in Treating Patients With Advanced Pancreatic Cancer NCT00028834 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction NCT00030498 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Combination Chemotherapy Plus Radiation Therapy With or Without Tipifarnib in Treating Patients With Locally A NCT00026104 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer NCT00028496 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Combination Chemotherapy and Radiation Therapy Plus Surgery in Treating Patients With Advanced Cancer of the P NCT00020345 | National Institutes of Health Clinical Center (CC) | Phase 2 |
| Completed | Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu NCT00004074 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer NCT00019006 | National Cancer Institute (NCI) | Phase 1 |
| Withdrawn | Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Panc NCT00253526 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic P NCT02575508 | Roswell Park Cancer Institute | Phase 1 / Phase 2 |